DEF: DT Cloud Seeks SPAC Extension, Waives Sponsor Fees

DT Cloud Acquisition Corporation proposes to extend its business combination deadline to February 2027 and waive monthly sponsor extension fees to facilitate its merger with Maius Pharmaceutical.

Summary

• DT Cloud Acquisition Corporation (DT Cloud) is holding an Extraordinary General Meeting on August 21, 2025, to vote on four key proposals.
• The primary proposals aim to extend the deadline for completing an initial business combination from up to eighteen times (until August 23, 2026) to up to twenty-four times (until February 23, 2027).
• A significant proposal is to waive the monthly extension fee of $60,000, previously required from the Sponsor for each one-month extension, effective from August 23, 2025, until February 23, 2027.
• The Investment Management Trust Agreement will also be amended to reflect these changes, and an Adjournment Proposal is included to allow for further proxy solicitation if insufficient votes are received.
• The Extension Amendment, Extension Fee Waiver, and Trust Amendment proposals are cross-conditioned on each other's approval.
• DT Cloud entered into a definitive business combination agreement with Maius Pharmaceutical Co., Ltd. on October 22, 2024.
• Public shareholders have the right to redeem their shares for approximately $11.00 per share from the Trust Account, compared to the closing share price of $10.95 on August 8, 2025.
• The Sponsor and insiders, holding approximately 67.7% of outstanding ordinary shares, intend to vote in favor of all proposals and have waived their redemption rights.

Sentiment

Score: 3

Explanation: The sentiment is negative because the company is seeking further extensions and, more critically, waiving sponsor contributions for these extensions. This indicates significant difficulties in closing the announced business combination and a reduced financial commitment from the sponsor, raising concerns about the deal's viability and the company's future.

Positives

• The proposed extension provides DT Cloud with additional time, until February 23, 2027, to complete its business combination with Maius Pharmaceutical, addressing macroeconomic and regulatory uncertainties.
• Waiving the monthly extension fee entirely provides maximum incentive for the Sponsor to continue extending the deadline without financial burden, increasing the likelihood of the business combination closing.
• Public shareholders retain their redemption rights, allowing them to exit their investment at a price slightly above the current market price ($11.00 per share vs. $10.95 closing price on August 8, 2025) if they choose not to participate in the extended timeline.
• The Board unanimously recommends approval of all proposals, indicating a unified management stance on the path forward.

Negatives

• The need for multiple extensions and the waiver of sponsor fees suggest difficulties in consummating the business combination within the originally anticipated timeframe, potentially indicating underlying challenges with the deal or market conditions.
• If the Extension Amendment is approved, the removal of funds from the Trust Account due to redemptions could significantly reduce the capital available for the business combination, potentially requiring additional fundraising.
• The waiver of the monthly extension fee means the Trust Account will not receive additional contributions from the Sponsor for extensions, which could reduce the per-share value for non-redeeming shareholders over time if the trust account's interest earnings are insufficient to offset expenses.
• The company cannot assure shareholders of sufficient liquidity to sell their shares in the open market, especially if the market price is lower than the redemption price.

Risks

• Inability to complete the initial business combination with Maius Pharmaceutical due to continued macroeconomic uncertainties, regulatory landscape, or failure to clear regulatory approvals (e.g., China Securities Regulatory Commission).
• Potential U.S. foreign investment regulations and review by entities like CFIUS, given the Sponsor's foreign ownership (80% held by a Macau passport holder), which could limit the pool of potential U.S. target companies or delay/prohibit the current business combination.
• Risk of liquidation if the business combination is not consummated by the extended deadline (February 23, 2027), resulting in public shareholders receiving only their pro rata portion of the Trust Account and rights expiring worthless.
• Significant redemptions by public shareholders could reduce the Trust Account balance, potentially requiring DT Cloud to seek additional funds to complete the business combination, which may not be available on favorable terms or at all.
• Lack of sufficient liquidity in DT Cloud's securities in the open market, making it difficult for shareholders to sell their shares when desired.

Future Outlook

DT Cloud aims to complete its initial business combination with Maius Pharmaceutical by February 23, 2027, leveraging the proposed extension and fee waiver to navigate macroeconomic and regulatory uncertainties. The Board believes these measures are necessary to provide shareholders with the opportunity to participate in an initial business combination, avoiding liquidation.

Management Comments

• "In light of the continued uncertainties in the macroeconomic environment and regulatory landscape, the Board has determined that it is in the best interests of the Company to seek Extension Amendment to allow for additional time and opportunity to clear regulatory approvals and consummate the business combination."
• "The Board has further determined that waiving the Monthly Extension Fee entirely will provide the Sponsor and its affiliates with maximum incentive to extend the deadline by which the Company must complete an initial business combination."
• "The Board believes that Proposal 1, Proposal 2 and Proposal 3 are necessary in order for the Company to be able to consummate an initial business combination."
• "Therefore, the Board has determined that it is in the best interests of our shareholders to approve Proposal 1, Proposal 2 and Proposal 3, which will provide our shareholders with the opportunity to participate in an initial business combination."

Industry Context

This filing reflects a common challenge faced by Special Purpose Acquisition Companies (SPACs) in the current market environment: the difficulty in identifying and consummating suitable business combinations within their initial deadlines. The need for multiple extensions and the waiver of sponsor contributions highlight the increased pressure on SPACs due to tighter regulatory scrutiny, volatile market conditions, and a more cautious investor sentiment towards de-SPAC transactions. The mention of regulatory approvals, specifically the China Securities Regulatory Commission, also points to the complexities of cross-border M&A, particularly involving Chinese entities, which have faced heightened regulatory hurdles and geopolitical considerations.

Comparison to Industry Standards

• The request for multiple extensions (up to 36 months from IPO) is becoming more common for SPACs struggling to close deals, moving away from the typical 18-24 month initial timelines. This aligns with a broader trend of SPACs seeking more time amidst a challenging de-SPAC market.
• The waiver of sponsor contributions for extensions is a notable deviation from the traditional SPAC model, where sponsors typically contribute funds to the trust account for each extension. This move, while incentivizing the sponsor, could be viewed negatively by some public shareholders as it removes the sponsor's 'skin in the game' for the extended period.
• The redemption value of $11.00 per share, slightly above the market price of $10.95, offers a de-risking opportunity for public shareholders, which is a standard feature of SPACs facing liquidation or extension votes. This provides a floor for the share price, a common characteristic of SPACs nearing their liquidation deadline or seeking extensions.

Corporate Governance

Related Party Transactions

• The Sponsor (DT Cloud Capital Corp.) and its affiliates hold 1,725,000 insider shares and 234,500 Private Placement Units, which would expire worthless if a business combination is not consummated, creating a strong incentive for them to approve the extensions.
• The Sponsor has agreed to advance up to $300,000 for liquidation costs if a business combination is not completed, and will not seek repayment for these expenses.
• The proposed waiver of the monthly extension fee directly benefits the Sponsor by removing their financial obligation to contribute funds for extensions.

Stakeholder Impact

• **Shareholders (Public)**: Provided with an opportunity to redeem shares at a slight premium to market price ($11.00 vs. $10.95), offering a de-risking option. Those who do not redeem will have their investment tied up for a longer period (until Feb 2027) with increased uncertainty, and without additional sponsor contributions to the trust account.
• **Sponsor (DT Cloud Capital Corp.)**: Benefits significantly from the waiver of monthly extension fees, removing a substantial financial burden and providing maximum incentive to continue pursuing the business combination without further cash outlays.
• **Maius Pharmaceutical Co., Ltd. (Target)**: Gains more time for regulatory approvals and closing the business combination, which is crucial for its public listing plans.
• **Management/Directors**: Their interests are aligned with the Sponsor, as their founder shares and private placement units would become worthless upon liquidation. The extension and fee waiver protect their investment and potential future roles in the combined entity.

Next Steps

• Hold an Extraordinary General Meeting on August 21, 2025, to vote on the proposed amendments.
• If approved, implement the extended business combination period until February 23, 2027, and waive the monthly extension fee from the Sponsor.
• Continue efforts to clear regulatory approvals and consummate the business combination with Maius Pharmaceutical Co., Ltd.
• Public shareholders must tender shares for redemption by August 19, 2025, if they wish to redeem.

Key Dates

Recommendation

The filing indicates significant challenges in closing the business combination, evidenced by the need for further extensions and the waiver of sponsor fees. While the extension provides a path forward and avoids immediate liquidation, the fee waiver removes a key incentive for the sponsor to contribute to the trust, potentially diluting the value for non-redeeming shareholders over time. The redemption option at a slight premium offers a de-risking opportunity for public shareholders. Given the uncertainties surrounding the business combination and the reduced sponsor commitment, a 'hold' recommendation is appropriate for those who have not yet redeemed, allowing them to monitor progress towards the business combination or consider redemption if the deal falters. For new investors, the risks outweigh the potential rewards at this stage.

Keywords

SPAC, Business Combination, Extension, Proxy Statement, Trust Account, Redemption Rights, Maius Pharmaceutical, Corporate Governance, SEC Filing, Investment Management Trust Agreement, CFIUS, Foreign Investment